Arbutus Biopharma to Participate in Upcoming Investor Conferences
February 04 2016 - 4:30PM
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading
therapeutic solutions company focused on developing a cure for
chronic hepatitis B virus (HBV) infection, today announced that the
company will be participating in two upcoming investor conferences.
- LEERINK Partners 5th Annual Global Healthcare Conferecne,
February 11, 2016, New York
- RBC Capital Markets 2016 Global Healthcare Conference, February
23-24, 2016, New York
Arbutus’ President and CEO, Dr. Mark J. Murray,
will present at the LEERINK conference on Thursday, February 11,
2016. A simultaneous webcast of the presentation can be accessed by
visiting the Investor sections of www.arbutusbio.com and selecting
Events and Presentations. Replays will be available on the Arbutus
website following the event.
About Arbutus Arbutus Biopharma
Corporation is a biopharmaceutical company dedicated to
discovering, developing and commercializing a cure for patients
suffering from chronic HBV infection. Our strategy is to
target the three pillars necessary to develop a curative regimen
for HBV: suppressing HBV replication within liver cells,
stimulating and reactivating the body’s immune system so that it
can mount an effective defense against the virus and, eliminating
the reservoir of viral genomic material known as covalently closed
circular DNA, or cccDNA that is the source of HBV persistence. Our
portfolio of assets includes a broad pipeline of drug candidates
for use in combination to develop a cure for HBV. To support
continuous discovery of potential novel drug candidates and
technologies, Arbutus has a research collaboration agreement with
the Baruch S. Blumberg Institute that provides exclusive rights to
in-license any intellectual property generated through the
collaboration. The Baruch S. Blumberg Institute was established in
2003 by the Hepatitis B Foundation.
Arbutus is headquartered in Vancouver, BC,
Canada with offices in Doylestown, PA, USA. For more information,
visit www.arbutusbio.com.
Contact Information
InvestorsAdam CutlerSenior Vice President,
Corporate AffairsPhone: 604.419.3200 Email:
acutler@arbutusbio.com
Helia BaradaraniManager, Investor
RelationsPhone: 604.419.3200Email: hbaradarani@arbutusbio.com
MediaPlease direct all media inquiries to:
media@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024
